Pharma BD Deal Intelligence

Merck KGaA / ImClone Systems Inc.

2007 · Co-Development · Complete

Amended Erbitux Japan co-development; Merck KGaA 50% / ImClone & BMS 25% each profit; 4.75% royalty to ImClone. Source: BioSpace, Fierce Biotech.

Key facts

• Announced Oct 31, 2007
• Deal type Co-Development

← Browse all deals  ·  How we score deals